Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
Clinical trial NCT01840579 · COMPLETED
Trial details
- NCT number
- NCT01840579
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-04-26
- Primary completion
- 2020-02-28
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.